,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['bcsm', 'breast', 'destinybreast04']
db04 destinybreast04 shows improvement in pfs and os in her2 low breast cancer, fundamentally changing the way we define the disease. #asco22 #bcsm 
Director Breast Oncology, Lifespan Cancer Institute, Legorreta Cancer Center Brown Univ | Medical Advisor @drloveresearch | #bcsm #clinicaltrials | Views Mine